December 6, 2013   Sweden
New scientific paper on treatment with the diabetes vaccine Diamyd®
The research group of Professor Johnny Ludvigsson at Linköping university have published a new paper in the scientific journal Diabetes/Metabolism Research and Reviews. In the paper they combine data from the previously published Phase II and Phase III clinical studies with the diabetes vaccine Diamyd® in children and adolescents with type 1 diabetes.

The new paper concludes that treatment with two doses of GAD-alum in children and adolescents with recent-onset type 1 diabetes shows no adverse events and preserves residual insulin secretion.

Dr Ludvigsson is the Principal Investigator of the ongoing clinical study DIABGAD-1 with the diabetes vaccine Diamyd®. The DIABGAD-1 study combines treatment with the diabetes vaccine Diamyd® with relatively high doses of vitamin D and the anti-inflammatory drug ibuprofen. The purpose of the treatment is to preserve the body's own ability to control the blood sugar level in children and adolescents newly diagnosed with type 1 diabetes.

Read the article here
Information presented here are not press releases and may include excerpts from and links to externally published content. Diamyd Medical is not responsible for externally published content.

Order GAD for preclinical research

GAD PRODUCTS